Loading...
OTCMTNBI
Market cap508kUSD
Dec 23, Last price  
0.02USD
1D
16.50%
1Q
86.40%
IPO
-97.69%
Name

Tanke Biosciences Corp

Chart & Performance

D1W1MN
OTCM:TNBI chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
9.64%
Rev. gr., 5y
%
Revenues
0k
000023,832,72728,561,82900000
Net income
-83k
L-15.92%
-7,043-18,518-21,665-29,865-3,136,094-210,24700-722,984-98,150-82,521
CFO
-75k
L+26.17%
-4,043-13,268-13,415-13,7223,544,279-1,184,09700-3,530-59,177-74,662

Profile

Tanke Biosciences Corporation, through its subsidiaries, develops, produces, markets, and sells animal nutrition and feed additive products. It operates in four segments: Organic Trace Mineral Additives, Functional Regulation Additives, Herbal Medicinal Additives, and Other. The company offers organic trace mineral additives under the Qili brand name; feed acidifiers, which are used to prevent microbial degradation of raw materials or finished feeds under the Qilicid name; seasonings; flavor enhancers that are used as the agent in the production of blended feed under the Tankeball name; and herbal medicinal additives blended with feed products under the Extra-Health, Qilimix, and Recoccider names. It also produces and markets multiple trace mineral premix products for livestock and poultry under the Qilimix name. In addition, the company provides natural sweeteners and attractants for use with feed for pigs, piglets, fish, and other aquatic animals under the Tankeball name; and water soluble organic multi-vitamin electrolyte, which is fed to animals through dissolving it in drinking water for the animals to consume. It serves mid-to-large sized feed product factories, large scale feed producers, and farmers. The company sells its products primarily in the People's Republic of China, Southeast Asia, and Latin America. Tanke Biosciences Corporation was founded in 1989 and is headquartered in Guangzhou, the People's Republic of China.
IPO date
Feb 10, 2011
Employees
130
Domiciled in
CN
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
8
256
1,335
Unusual Expense (Income)
NOPBT
(8)
(256)
(1,335)
NOPBT Margin
Operating Taxes
(83)
Tax Rate
NOPAT
74
(256)
(1,335)
Net income
(83)
-15.92%
(98)
-86.42%
(723)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
140
53
2
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
137
46
(40)
Cash flow
Cash from operating activities
(75)
(59)
(4)
CAPEX
2
Cash from investing activities
Cash from financing activities
70
25
45
FCF
19
(279)
(1,277)
Balance
Cash
3
7
41
Long term investments
Excess cash
3
7
41
Stockholders' equity
(13,116)
(13,034)
(12,952)
Invested Capital
13,160
12,999
12,893
ROIC
0.57%
ROCE
729.84%
2,294.92%
EV
Common stock shares outstanding
21,113
12,476
12,746
Price
Market cap
EV
EBITDA
(256)
(1,335)
EV/EBITDA
Interest
56
56
2
Interest/NOPBT